Food and Drug Administration Revitalization Act
The 2007 Food and Drug Administration Revitalization Act, which never passed the House, would have established a surveillance system to monitor the negative effects of drugs and medical devices after they had been put on the market. The legislation would have expanded and strengthened the drug safety wing of the FDA. New fines for misleading advisements and failure to perform follow up safety studies were also included in the law.